v3.23.2
Summary of Significant Accounting Policies - Revenue and Gross Accounts Receivable By Major Customer (Details) - Customer Concentration Risk
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Percent of Total Gross Revenues | Fresenius Medical Care Rx      
Concentration Risk [Line Items]      
Concentration risk percentage 34.00% 33.00% 29.00%
Percent of Total Gross Revenues | Otsuka Pharmaceutical Co. Ltd.      
Concentration Risk [Line Items]      
Concentration risk percentage 20.00% 14.00% 29.00%
Percent of Total Gross Revenues | AmerisourceBergen Drug Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 15.00% 16.00% 12.00%
Percent of Total Gross Revenues | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 0.00% 13.00% 11.00%
Percent of Total Gross Revenues | Cardinal Health, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage 0.00% 11.00% 0.00%
Percent of Gross Accounts Receivable | Fresenius Medical Care Rx      
Concentration Risk [Line Items]      
Concentration risk percentage 44.00% 16.00%  
Percent of Gross Accounts Receivable | Otsuka Pharmaceutical Co. Ltd.      
Concentration Risk [Line Items]      
Concentration risk percentage 0.00% 22.00%  
Percent of Gross Accounts Receivable | AmerisourceBergen Drug Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 16.00% 15.00%  
Percent of Gross Accounts Receivable | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 0.00%  
Percent of Gross Accounts Receivable | Cardinal Health, Inc.      
Concentration Risk [Line Items]      
Concentration risk percentage 13.00% 10.00%  
Percent of Gross Accounts Receivable | MTPC      
Concentration Risk [Line Items]      
Concentration risk percentage 0.00% 20.00%